64 related articles for article (PubMed ID: 15217942)
1. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Watanabe T; Tobinai K; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Matsuno Y; Tsukasaki K; Nagai H
Br J Haematol; 2024 Mar; 204(3):849-860. PubMed ID: 37996986
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
3. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.
Fury MG; Lipton A; Smith KM; Winston CB; Pfister DG
Cancer Immunol Immunother; 2008 Feb; 57(2):155-63. PubMed ID: 17602224
[TBL] [Abstract][Full Text] [Related]
4. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.
Kaprio E; Prusila R; Tokola S; Kuusisto MEL; Jantunen E; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38164067
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
7. An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia.
Zhang X; Rao M; Xu G
Arch Med Sci; 2024; 20(2):494-505. PubMed ID: 38757021
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma.
Takemura S; Tomita N; Koharazawa H; Fujimaki K; Harano H; Hyo R; Yamazaki E; Hashimoto C; Miyazaki T; Ishigatsubo Y
Int J Hematol; 2012 Aug; 96(2):241-6. PubMed ID: 22684897
[TBL] [Abstract][Full Text] [Related]
9. Combination strategies to enhance antitumor ADCC.
Kohrt HE; Houot R; Marabelle A; Cho HJ; Osman K; Goldstein M; Levy R; Brody J
Immunotherapy; 2012 May; 4(5):511-27. PubMed ID: 22642334
[TBL] [Abstract][Full Text] [Related]
10. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.
Cheng YC; Valero V; Davis ML; Green MC; Gonzalez-Angulo AM; Theriault RL; Murray JL; Hortobagyi GN; Ueno NT
Br J Cancer; 2010 Oct; 103(9):1331-4. PubMed ID: 20877352
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Olin RL; Kanetsky PA; Ten Have TR; Nasta SD; Schuster SJ; Andreadis C
Am J Hematol; 2010 Apr; 85(4):255-60. PubMed ID: 20196173
[TBL] [Abstract][Full Text] [Related]
12. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.
Riaz W; Hernandez-Ilizaliturri FJ; Czuczman MS
Immunol Res; 2010 Mar; 46(1-3):192-205. PubMed ID: 19763890
[TBL] [Abstract][Full Text] [Related]
13. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature.
Siddhartha G; Vijay P
J Hematol Oncol; 2009 Mar; 2():14. PubMed ID: 19309523
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
17. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
